Sglt 2 denied due to quantity / dose limits by Aetna?

Aetna's specific coverage criteria for sglt2 are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Limits the Quantity of Your SGLT2 Inhibitor — and How to Appeal

SGLT2 inhibitors are a class of oral medications used to manage type 2 diabetes and, depending on the specific agent, to reduce cardiovascular or kidney disease progression. Aetna's quantity-limit restrictions reflect the doses and supply intervals specified in the FDA-approved prescribing information and the plan's coverage policy. When your prescription exceeds those limits — whether because your prescriber selected a different dosing interval, a higher strength, or a larger supply — a quantity-limit denial is the likely result.

### Why This Denial Is Routinely Appealable

Quantity-limit denials are among the most successfully overturned drug denials because they are almost always tied to a fixable documentation gap rather than a clinical disagreement. Your prescriber's rationale — why the prescribed quantity is medically necessary for your specific situation — is almost never captured in the initial authorization request. An appeal gives you the opportunity to supply that rationale with supporting chart documentation.

### Federal Appeal Framework

Every insured plan must follow a structured internal-and-external review process:

• Internal appeal: You have the right to a full-and-fair internal review under ERISA §503 (employer-sponsored plans) or your state's equivalent. File within the deadline shown on your denial letter — typically 180 days from the denial date.
• External review: If the internal appeal is denied, ACA §2719 entitles most enrollees to an independent external review. The external-review window is generally within four months of a final internal denial. An accredited independent review organization — not Aetna — renders the decision, and Aetna must comply.
• Expedited option: If waiting for standard review would seriously jeopardize your health, request an expedited internal and/or expedited external review. Expedited decisions are typically issued within 72 hours.

### Concrete Appeal Steps and Timeline

1. Obtain the denial letter and identify the exact quantity-limit rule Aetna applied. 2. Download Aetna's current published medical and drug coverage policy for SGLT2 inhibitors — the policy number and effective date appear on the denial or are available on Aetna's website. 3. Review the FDA-approved prescribing label for the specific SGLT2 inhibitor dispensed — it specifies approved dosing ranges. 4. Ask your prescriber to draft a medical-necessity letter explaining why the quantity prescribed falls within FDA-approved use and is appropriate for your clinical situation. 5. File the internal appeal with the supporting documentation before the deadline. 6. If denied internally, file for external review immediately.

### Documentation to Gather

• Diagnosis confirmation: Chart notes and lab reports confirming the condition being treated.
• Prior treatment history: Dated records of other medications tried, with durations and outcomes.
• Clinical severity: Physician notes documenting disease stage or severity relevant to dosing decisions.
• Prescriber letter: A signed letter mapping the prescribed quantity to an FDA-approved use and explaining the clinical reason the standard quantity limit is insufficient.

### Criteria-Mapping Structure

For each requirement listed in Aetna's quantity-limit policy, locate the corresponding fact in the medical record and state it explicitly in the appeal. For example: if the policy requires documentation that the prescribed strength is within an FDA-approved dosing range, cite the prescribing label page and attach it. Unanswered criteria are the most common reason internal appeals fail.